Progress in Understanding Androgen-Independent Prostate Cancer (AIPC): A Review of Potential Endocrine-Mediated Mechanisms

European Urology

Volumn 53, Issue 6, 2008, Pages 1129-1137

  Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Androgen receptor; Androgens; Cholesterol; Escape mechanisms; Prostate cancer; Statins

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANE DERIVATIVE; ANDROSTANOLONE; ANTIANDROGEN; DOCETAXEL; EPIDERMAL GROWTH FACTOR; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; KERATINOCYTE GROWTH FACTOR; PREGNENOLONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; SOMATOMEDIN C; TRANSCRIPTION FACTOR ERG; TRASTUZUMAB;

ANDROGEN SYNTHESIS; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER STEM CELL; CANCER SURVIVAL; CANCER TISSUE; CASTRATION; CLINICAL TRIAL; DIMERIZATION; DISEASE COURSE; DNA BINDING; DRUG MECHANISM; ENDOCRINE FUNCTION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE MUTATION; HORMONAL THERAPY; HUMAN; METASTASIS; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TMPRSS2 GENE;

ANDROGENS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 42749084744     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.01.049     Document Type: Review

References (58)

1. Huggins C. Endocrine-induced regression of cancers. Cancer Res 27 (1967) 1925-1930
2. Blackard C.E., Byar D.P., and Jordan W.P. Orchiectomy for advanced prostatic carcinoma. Urology 1 (1973) 553-560
3. Bill-Axelson A., Holmberg L., Ruutu M., et al., Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977-1984
4. Holmberg L., Bill-Axelson A., Garmo H., et al., SPCG-4 Study Group. Prognostic markers under watchful waiting and radical prostatectomy. Hematol Oncol Clin North Am 20 (2006) 845-855
5. Globocan 2002 (www.clip.iarc.fr). Accessed 18.12.2007.
6. SEER data base (www.seer.cancer.gov/csr). Accessed 18.12.2007.
7. Oliver S.E., May M.T., and Gunnell D. International trends in prostate cancer mortality in the PSA-era. Int J Cancer 92 (2001) 893-898
8. Schröder FH. New developments in screening and early detection of prostate cancer. In: McConnell DL, Akaza H, Khoury S, Schalken J, (eds.), Prostate cancer, ed. 21. Paris, France: 2006, p. 215-46.
9. Bolla M., van Poppel H., Collette L., et al., European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
10. Platz E.A., Leitzmann M.F., Visvanathan K., et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98 (2006) 1819-1825
11. Labrie F., Dupont A., Belanger A., et al. New approaches in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 4 (1983) 579-594
12. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491-8.
13. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339 (1998) 1036-1042
14. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nature 1 (2001) 34-45
15. Grossmann M.E., Huang H., and Tindall T.J. Androgen receptor signalling in androgen refractory prostate cancer. J Natl Cancer Inst 22 (2001) 1687-1697
16. Coffey D.S., and Isaacs J.T. Control of prostate growth. Urology 3 Suppl (1981) 17-24
17. Isaacs J.T. The biology of hormone-refractory prostate cancer. Why does it develop?. Urol Clin North Am 26 (1999) 263-273
18. McDonnell T.J., Troncoso P., Brisbay S.M., et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52 (1992) 6940-6944
19. Revelos K., Petraki C., Gregorakis A., Scorilas A., Papanastasiou P., and Koutsilieris M. Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res 25 (2005) 3123-3133
20. Chi K.N. Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer. World J Urol 23 (2005) 33-37
21. Zhang Z., Li M., Wang H., Agrawal S., and Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A 100 (2003) 11636-11641
22. Liu W., Bulgaru A., Haigentz M., Stein C.A., Perez-Soler R., and Mani S. The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics. Curr Med Chem Anticancer Agents 3 (2003) 217-223
23. Verhagen P.C., van Duijn P.W., Hermans K.G., et al. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 208 (2006) 699-707
24. Ma X., Ziel-van der Made A.C., Autar B., et al. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 65 (2005) 5730-5739
25. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
26. Culig Z., Hobisch A., Cronauer M.V., et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54 (1994) 5474-5478
27. Ziada A., Barqawi A., Glode L.M., et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60 (2004) 332-337
28. van der Kwast T.H., Schalken J., Ruizeveld de Winter J.A., et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48 (1991) 189-193
29. Ruizeveld de Winter J.A., Janssen P.J., Sleddens H.M., et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144 (1994) 735-746
30. Visakorpi T., Hyytinen E., Koivisto P., et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9 (1995) 401-406
31. Koivisto P., Kononen J., Palmberg C., et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57 (1997) 314-319
32. Haapala K., Kuukasjarvi T., Hyytinen E., Rantala I., Helin H.J., and Koivisto P.A. Androgen receptor amplification is associated with increased cell proliferation in prostate cancer. Hum Pathol 38 (2007) 474-478
33. de Jong F.H., Reuvers P.J., Bolt-de Vries J., Mulder E., Blom J.H., and Schroeder F.H. Androgens and androgen-receptors in prostate tissue from patients with benign prostatic hyperplasia: effects of cyproterone acetate. J Steroid Biochem Mol Biol 42 (1992) 49-55
34. Labrie F., Dupont A., Belanger A., et al. Treatment of prostate cancer with gonadotropin-releasing hormone agonists [review]. Endocr Rev 7 (1986) 67-74
35. Gregory C.W., Johnson Jr. R.T., Mohler J.L., French F.S., and Wilson E.M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61 (2001) 2892-2898
36. Quigley C.A., De Bellis A., Marschke K.B., el-Awady M.K., Wilson E.M., and French F.S. Androgen receptor defects: historical, clinical, and molecular perspectives [review] (erratum in Endocr Rev 1995 Aug;16(4):546). Endocr Rev 16 (1995) 271-321 (no abstract available)
37. Veldscholte J., Berrevoets C.A., Ris-Stalpers C., et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens [review]. J Steroid Biochem Mol Biol 41 (1992) 665-669
38. Marcelli M., Ittmann M., Mariani S., et al. Androgen receptor mutations in prostate cancer. Cancer Res 60 (2000) 944-949
39. Ruijter E., van de Kaa C., Miller G., Ruiter D., Debruyne F., and Schalken J. Molecular genetics and epidemiology of prostate carcinoma [review]. Endocr Rev 20 (1999) 22-45
40. Small E.J., and Srinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76 (1995) 1428-1434
41. Taplin M.E., Bubley G.J., Ko Y.J., et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59 (1999) 2511-2515
42. Taplin M.E., Rajeshkumar B., Halabi S., et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 1993. J Clin Oncol 21 (2003) 2673-2678
43. Hermans K.G., van Marion R., van Dekken H., Jenster G., van Weerden W.M., and Trapman J. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 66 (2006) 10658-10663
44. Winnes M., Lissbrant E., Damber J.E., and Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 17 (2007) 1033-1036
45. Laxman B., Tomlins S.A., Mehra R., et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8 (2006) 885-888
46. Tu J.J., Rohan S., Kao J., Kitabayashi N., Mathew S., and Chen Y.T. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 20 (2007) 921-928
47. Cerveira N., Ribeiro F.R., Peixoto A., et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8 (2006) 826-832
48. Mehra R., Tomlins S.A., Shen R., et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20 (2007) 538-544
49. Nam R.K., Sugar L., Yang W., et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 97 (2007) 1690-1695
50. Demichelis F., Fall K., Perner S., et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26 (2007) 4596-4599
51. Attard G., Clark J., Ambroisine L., et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27 (2007) 253-263
52. Stanbrough M., Bubley G.J., Ross K., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 (2006) 2815-2825
53. Montgomery B., Mostaghel E., Vessella R., et al. Androgen synthesis in castration-adapted metastatic prostate cancer. ASCO Prostate Meeting 2007. Orlando, Florida, USA, 22-24 February (2007) (abstract no. 98)
54. Titus M.A., Schell M.J., Lih F.B., Tomer K.B., and Mohler J.L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11 (2005) 4653-4657
55. Titus M.A., Gregory C.W., Ford III O.H., Schell M.J., Maygarden S.J., and Mohler J.L. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 11 (2005) 4365-4371
56. Pezzi V., Mathis J.M., Rainey W.E., and Carr B.R. Profiling transcript levels for steroidogenic enzymes in fetal tissues. J Steroid Biochem Mol Biol 87 (2003) 181-189
57. Goldstein NI. Cholesterol synthesis in the prostate gland and its relationship to benign prostatic hyperplasia. Ph.D. dissertation, Rutgers University, New Brunswick, NJ, 1975.
58. O'Donnell A., Judson I., Dowsett M., et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90 (2004) 2317-2325